NCT05904457 - A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions

Solid TumorsAdvanced Solid TumorsMetastatic Cancer

Interventions

DRUG

bevacizumab

Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.

DRUG

erlotinib

Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.

Trial Locations (10)

13496

RECRUITING

Cha University Bundang Medical Center, Seongnam-si

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

21565

RECRUITING

Gachon University Gil Medical Center, Incheon

35015

RECRUITING

Chungnam National University Hospital, Daejeon

44033

RECRUITING

Ulsan University Hospital, Ulsan

52727

RECRUITING

Gyeongsang National University Hospital, Jinju

02841

RECRUITING

Korea University Anam Hospital, Seoul

03722

RECRUITING

Yonsei Cancer Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06591

RECRUITING

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul